Roche announced the results of its Phase III persevERA Breast Cancer study, revealing a mixed outcome for giredestrant (investigational drug designation GDC-9545), a novel selective estrogen receptor degrader (SERD), in combination with palbociclib for first-line treatment of advanced ER-positive breast cancer. While the study did not achieve statistical significance for its primary endpoint of progression-free survival (PFS), a numerical improvement was observed. However, the results have not dampened the pharmaceutical giant’s enthusiasm, as the FDA has already accepted the company’s New Drug Application based on positive data from the evERA trial in the second-line setting.
persevERA Study: Navigating Clinical Complexity
The persevERA trial investigated giredestrant plus palbociclib against the standard combination of letrozole plus palbociclib in 992 patients with hormone receptor-positive (ER+), HER2-negative, locally advanced or metastatic breast cancer. Despite failing to meet statistical significance on its primary endpoint of investigator-assessed PFS, the combination demonstrated a numerical advantage, leaving the door open for further investigation.
While persevERA didn’t meet its primary objective, we are confident in the potential of giredestrant to become a new standard-of-care endocrine therapy in early and advanced ER-positive breast cancer.
Dr. Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche
FDA Acceptance and Regulatory Progress
A critical highlight for Roche came with the FDA’s recent acceptance of the New Drug Application (NDA) for giredestrant based on the positive Phase III evERA trial data. The evERA study evaluated giredestrant plus everolimus versus standard-of-care endocrine therapy plus everolimus in second-line (2L+) advanced ER-positive, HER2-negative breast cancer.
Additionally, Roche plans to submit Phase III lidERA data in early-stage breast cancer to the FDA within the coming weeks. The lidERA trial compared giredestrant monotherapy to standard-of-care endocrine therapy as adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. These sequential regulatory submissions position giredestrant as a potential treatment option across multiple disease settings and stages of ER-positive breast cancer.
Read More: Elecsys PRO-C3: Roche’s Precision Test for Liver Fibrosis
A Comprehensive Clinical Development Program
Roche’s approach to developing giredestrant reflects a sophisticated understanding of ER-positive breast cancer’s heterogeneity. The company has designed distinct Phase III studies tailored to specific disease biology and disease stages:
- lidERA (Adjuvant Setting): Giredestrant vs. standard-of-care endocrine therapy for early-stage ER+/HER2- breast cancer.
- persevERA (First-Line Metastatic): Giredestrant plus palbociclib vs. letrozole plus palbociclib for endocrine-sensitive ER+/HER2- metastatic breast cancer.
- pionERA (First-Line Metastatic): Giredestrant plus physician’s choice of CDK4/6 inhibitor vs. fulvestrant plus CDK4/6 inhibitor for endocrine-resistant ER+/HER2- metastatic breast cancer (expected readout in 2027).
- evERA (Second-Line Metastatic): Giredestrant plus everolimus vs. standard-of-care endocrine therapy plus everolimus (already positive).
- heredERA (First-Line HER2+ Metastatic): Giredestrant plus Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous) vs. Phesgo monotherapy in HER2-positive metastatic breast cancer.
This multifaceted approach demonstrates Roche’s commitment to identifying which patient populations will benefit most from giredestrant across different disease stages and molecular subtypes.
Building on Earlier Successes
The persevERA setback must be contextualized within the broader giredestrant development narrative. The earlier Phase III evERA trial demonstrated clear efficacy, validating the molecule’s clinical activity as a SERD. This positive evERA result was sufficient to secure FDA acceptance of the NDA.
Furthermore, the Phase III lidERA trial in early-stage disease proved successful, generating data that Roche is now submitting to the FDA. The Phase II coopERA neoadjuvant trial also provided supporting evidence, showing that giredestrant was superior to an aromatase inhibitor in reducing Ki67 levels—a marker of malignant cell division.
What’s Next for Giredestrant?
Looking ahead, Roche has outlined a path forward that includes exploring giredestrant in the adjuvant (post-surgery) setting combined with CDK4/6 inhibitors. The company is also awaiting the readout of the pionERA study, another first-line metastatic trial evaluating giredestrant with physician’s choice of CDK4/6 inhibitor, which is expected to provide results in 2027.
The FDA’s acceptance of the NDA is a significant regulatory milestone, particularly given the positive evERA data supporting its use in the second-line setting for advanced ER-positive breast cancer. If approved, giredestrant would represent a new endocrine therapy option for patients who have progressed on prior treatments.
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, […]
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regeneron says the CHMP has recommended EU approval of an alternative Libtayo dosing schedule: 700 mg every six weeks after an initial 12-week regimen of […]
Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease […]
Clinical Significance
ER-positive breast cancer remains one of the most common forms of the disease, affecting hundreds of thousands of women worldwide annually. Despite decades of endocrine therapy development, including aromatase inhibitors, tamoxifen, and fulvestrant, treatment resistance remains a significant clinical challenge. SERDs like giredestrant represent the next evolution in this therapeutic class, offering potentially superior mechanisms of action through complete estrogen receptor degradation.
The diversity of Roche’s clinical program, spanning early-stage adjuvant settings, first-line metastatic disease (both endocrine-sensitive and endocrine-resistant), second-line metastatic disease, and HER2-positive disease, reflects the complexity of ER-positive breast cancer and the need for tailored therapeutic approaches.
Last Modified:
